Scarica l'app Stockscreener
8.20
4.24%
0.41
Precedente Chiudi:
$7.79
Aprire:
$7.78
Volume 24 ore:
39,633
Relative Volume:
0.49
Capitalizzazione di mercato:
$188.74M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+15.67%
1M Prestazione:
+21.74%
6M Prestazione:
+6.01%
1 anno Prestazione:
+10.48%
Intervallo 1D:
$7.78
$8.3037
Intervallo di 1 settimana:
$6.87
$8.49
Portata 52W:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Nome
Actuate Therapeutics Inc
Settore
Industria
Telefono
847-986-4190
Indirizzo
1751 RIVER RUN, FORT WORTH
Confronta ACTU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.12 | 181.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.80 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.08 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.50 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.08 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-26 | Iniziato | B. Riley Securities | Buy |
| 2025-04-22 | Iniziato | Craig Hallum | Buy |
| 2025-03-17 | Iniziato | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Borsa (ACTU) Ultime notizie
Using Bollinger Bands to evaluate Actuate Therapeutics Inc.Trade Volume Summary & Long-Term Growth Portfolio Plans - newser.com
Actuate Therapeutics Inc. stock retracement – recovery analysisWeekly Trend Report & Entry Point Strategy Guides - newser.com
Heatmap analysis for Actuate Therapeutics Inc. and competitorsSell Signal & Safe Entry Trade Reports - newser.com
How to forecast Actuate Therapeutics Inc. trends using time series2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Risk vs reward if holding onto Actuate Therapeutics Inc.Dollar Strength & Real-Time Market Trend Scan - newser.com
How hedge fund analytics apply to Actuate Therapeutics Inc. stock2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Will Actuate Therapeutics Inc. stock see insider buyingPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Can Actuate Therapeutics Inc. stock deliver sustainable ROETrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Reversal indicators forming on Actuate Therapeutics Inc. stock2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart.com
Actuate Therapeutics (NASDAQ:ACTU) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Applying Elliott Wave Theory to Actuate Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - newser.com
Price action breakdown for Actuate Therapeutics Inc.Market Volume Report & Growth Focused Investment Plans - newser.com
Is Actuate Therapeutics Inc. trending in predictive chart models2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Evaluating Actuate Therapeutics Inc. with trendline analysisJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
How to build a custom watchlist for Actuate Therapeutics Inc.2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Is Actuate Therapeutics Inc. forming a reversal patternWeekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating - 富途牛牛
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
B.Riley Financial Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Relative strength of Actuate Therapeutics Inc. in sector analysisPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-02 23:42:39 - newser.com
Ataxia Telangiectasia Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Actuate Therapeutics Inc Stock Analysis and ForecastHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
Goldman Sachs Group Inc. Has $151,000 Holdings in Actuate Therapeutics, Inc. $ACTU - Defense World
Myelofibrosis Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Myelofibrosis Market Outlook 2034Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - openPR.com
Published on: 2025-09-29 03:19:58 - newser.com
What analysts say about Actuate Therapeutics Inc stockShort-Term Trading Alerts & Trade Like a Pro Using AI Edge - Early Times
Actuate Therapeutics Inc Azioni (ACTU) Dati Finanziari
Non sono disponibili dati finanziari per Actuate Therapeutics Inc (ACTU). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Actuate Therapeutics Inc Azioni (ACTU) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
| Fletcher Aaron G.L. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):